KMT2A and acute lymphoblastic leukemia: The chemo‐sensitizing capability of decitabine was assessed by performing a combinatorial screen of decitabine with prednisone, asparaginase, cytarabine, daunorubicin, or vincristine, which represent cornerstone drugs in current MLL‐rearranged infant ALL treatment [2, 3].